Table Info

Table 1.

Correlation between therapy, adverse events and hematological/biochemical parameters

ATRA 45 mg/m²/d	Idarubicin 12 mg/m²/d	Day of induction therapy	Adverse events	WBC	N	PB	Hb	PLT	FD	D-D	PT	PTT	LDH	CRP
Started		1		16.68	4.5	59	9	66	88	12429	1.27	0.97	2216	1.74
Interrupted		2	Differentiation syndrome	23.47	5.9	70	11.4	63	136	3633	1.07	0.77	1587	2.21
	1st Infusion	3	Bradycardia	49.90	5.99	79	10.2	25	117	34762	1.36	0.87	18440	8.38
		4		35.67	7.49	63	9	26	231	38773	1.24	0.79	16700	9
	2nd Infusion	5		19.86	6.16	52	9.5	39	189	38167	1.19	0.76	9592	12.27
Resumed at 50%		6		13.23	5.03	34	10.4	54	116	27330	1.15	0.73	5249	5.11
	3rd Infusion	7		5.98	2.09	28	10.6	48	67	17797	1.21	0.77	3456	1.7
		8		1.39	NE	NE	9.4	29	105	12442	1.19	0.74	2138	0.97
	4th Infusion	9		0.7	NE	NE	9.2	61	97	12203	1.2	0.72	1700	0.6
		10		0.4	NE	NE	8.5	45	126	9643	1.12	0.74	1330	0.42
		11		0.3	NE	NE	9.5	49	117	9021	1.14	0.77	1085	0.33
Resumed at 100%		12		0.15	NE	NE	9.6	69	124	6575	1.19	0.75	978	0.24
Interrupted		13	Ischemic segmentary ileitis	0.12	NE	NE	10.2	40	128	6273	1.14	0.72	893	0.53
		14		0.05	NE	NE	9.8	49	248	9265	1.36	0.87	800	4.4
		15	Paroxysmal supraventricular tachycardia	0.07	NE	NE	12.1	50	382	8559	1.38	0.92	710	29.98
		16		0.05	NE	NE	11.1	24	490	5191	1.45	0.93	641	43.48
		17	Pulmonary emboly	0.06	NE	NE	12.3	33	786	4902	1.32	1.04	532	40.71
		18		0.09	NE	NE	11	41	799	3345	1.12	0.91	498	35.45
		19		0.1	NE	NE	11	38	430	6565	1.05	0.75	494	13.78
		20		0.21	NE	NE	11	18	279	4496	1.23	0.85	623	6.65
Resumed at 100%		30	Ischemic segmentary ileitis	3.42	3.1	0	8.7	261	580	1535	1.16	0.92	550	5.1
Interrupted		31	Differentiation syndrome	3.78	3.36	0	9.7	291	449	1230	1.12	0.96	532	4.96

WBC: white blood cells, 10⁹/L; N: neutrophils, 10⁹/L; PB: peripheral blasts, %; Hb: hemoglobin, g/dL; PLT: platelets, 10⁹/L; FD: fibrinogen, mg/dL; D-D: D-dimer, ng/mL; PT: prothrombin time; PTT: partial thromboplastin time; LDH: lactic dehydrogenase, U/L; CRP: C-reactive protein, g/dL; NE: not evaluable

Declarations

Author contributions

VF and MS ideated and wrote the manuscript; UG created the figures. All authors contributed to manuscript revision, read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with Helsinki Declaration of 1975.

Consent to participate

The informed consent to participate in the study was obtained from all participants.

Consent to publication

The informed consent to publication was obtained from relevant participants.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Breccia M, Lo Coco F. Thrombo-hemorrhagic deaths in acute promyelocytic leukemia. Thromb Res. 2014;133 Suppl 2:S112–6. [DOI] [PubMed]

Ipec Y, Hulya D, Melih A. Disseminated exfoliativedermatitis associated with all-transretinoic acid in the treatment of acute promyelocytic leukemia. Case ReportsMed. 2012;2012:236174. [DOI]

Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94:1192–200. [PubMed]

Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021–8. [DOI] [PubMed]

LoCoco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111–21. [DOI] [PubMed]

Fenaux P, De Boutton S. Retinoic acid syndrome.Recognition, prevention and management. Drug Saf. 1998;18:273–9. [DOI] [PubMed]

Sanz MA, Lo Coco F, Martín G, Avvisati G, Rayón C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247–53. [PubMed]

Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med. 1992;117:292–6. [DOI] [PubMed]

Holmes D, Vishnu P, Dorer RK, Aboulafia DM. All-trans retinoic acid-induced pseudotumor cerebri during induction therapy for acute promyelocytic leukemia: a case report and literature review. Case Rep Oncol Med. 2012;2012:313057. [DOI] [PubMed] [PMC]

10.

Choi S, Kim HS, Jung CS, Jung SW, Lee YJ, Rheu JK, et al. Reversible symptomatic myocarditis induced by all-trans retinoic acid administration during induction treatment of acute promyelocytic leukemia: rare cardiac manifestation as a retinoic acid syndrome. J Cardiovasc Ultrasound. 2011;19:95–8. [DOI] [PubMed] [PMC]

11.

Citak FE, Ezer U, Akkaya E, Ozbulbul N, Bahce M, Kurekci AE. All-trans-retinoic acid-induced myositis in a child with acute promyelocytic leukemia. Haematologica. 2006;91 Suppl 8:ECR35. [PubMed]

12.

Park CJ, Bae YD, Choi JY, Heo PS, Lee KS, Park YS, et al. Sweet’s syndrome during the treatment of acute promyelocytic leukemia with all-trans retinoic acid. Korean J Intern Med. 2001;16:218–21. [DOI] [PubMed] [PMC]

13.

Shimizu D, Nomura K, Matsuyama R, Matsumoto Y, Ueda K, Masuda K, et al. Scrotal ulcers arising during treatment with all-trans retinoic acid for acute promyelocytic leukemia. Intern Med. 2005;44:480–3. [DOI] [PubMed]

14.

McGregor A, Hurst E, Lord S, Jones G. Bradycardia following retinoic acid differentiation syndrome in a patient with acute promyelocytic leukaemia. BMJ Case Rep. 2012;2012:bcr0220125848. [DOI]

15.

Maruhashi K, Wada H, Taniguchi M, Koizumi S. Sinus bradyarrhythmia during administration of all-trans retinoic acid in a patient with acute promyelocytic leukemia. Rinsho Ketsueki. 1996;37:443–7. Japanese. [PubMed]

16.

Farah RA, Jalkh KS, Farhat HZ, Sayad PE, Kadri AM. Acquired protein C deficiency in a child with acute myelogenous leukemia, splenic, renal, and intestinal infarction. Blood Coagul and Fibrinolysis. 2011;22:140–3. [DOI]

17.

Yamada K, Sugimoto K, Matsumoto T, Narumi K, Oshimi K. All-trans retinoic acid-induced vasculitis and hemonecrosis of the ileum in a patient with acute promyelocytic leukemia. Leukemia. 1999;13:647–8. [DOI] [PubMed]

18.

Bhargava R, Dolai TK, Singhal D, Kumar R, Pathak P. Retinoic acid syndrome after first dose of ATRA and ileal perforation secondary to promyelocytes infiltration. Leuk Res. 2008;32:997–8. [DOI] [PubMed]

19.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45. [DOI] [PubMed]

20.

Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538. [PubMed]